Contattaci contattaci
logo
logo

Biofarma Group Announces Group CFO Transition

Data: 24_10_2024
Categoria: Comunicati Stampa
Home / Press Room / Biofarma Group Announces Group CFO Transition

This press release may constitute a public disclosure of inside information by Kepler S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.

Milan, Italy – 24th October 2024 – The Biofarma Group, the largest global CDMO focused on nutraceuticals, controlled by Ardian together with the Scarpa and the Luhadia families, announces that Group CFO Stefano Cavacini has decided to step down from his role to pursue another opportunity. The role has been already taken up by Andrea Esposito, who has been appointed as new Group CFO of the Biofarma Group.

Andrea Esposito has over 20 year of corporate finance experience. Mr. Esposito has previously served as Group CFO in Italtractor ITM S.p.A., Custom S.p.A. and Officine Maccaferri S.p.A. He also served in various executive roles at Datalogic S.p.A., including as CFO Americas, and, prior to that, served as a Director in Deloitte.

The Biofarma Group is grateful for Stefano’s contribution and gives its warmest welcome to Andrea. His entry gives continuity to a path of strengthening of managerial structures with international profiles to prepare Biofarma Group for the global challenges and opportunities ahead.

Forward Looking Statements

This press release may include “forward-looking statements” within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding the Biofarma Group’s intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.

> Scarica pdf
logo
© Biofarma Srl C.F. e P.IVA 02895910301
T. +39 0432 868711 F. +39 0432 868018
Via Castelliere, 2
33036 Mereto di Tomba (UD) Italy
Numero REA UD - 296214
Data di iscrizione al Registro delle
Imprese di UDINE: 01/07/2017
Numero d'iscrizione: 02895910301
Capitale sociale euro 3.000.000